# GI Side Effects in Quad-Agonist GLP Drugs: Expectations for Improvement

Canonical source: https://retacompare.com/research/gi-side-effects-in-quad-agonist-glp-drugs-will-they-improve

Safety · 2026-05-02


    This article explores the gastrointestinal side effects associated with quad-agonist GLP drugs, particularly nausea, vomiting, and constipation, while examining how amylin and Y2 receptor components may mitigate these adverse effects.

The big picture

After the introduction of Retatrutide, the landscape of obesity and metabolic disease management is evolving rapidly. The next generation of multi-agonist therapies, particularly quad-agonists, are being developed to enhance efficacy while addressing the limitations of current treatments. However, gastrointestinal (GI) side effects remain a significant concern, influencing patient adherence and overall treatment success. Understanding the mechanisms behind these side effects and how they might be alleviated is crucial as the field progresses.

How it works

Quad-agonist GLP drugs target multiple receptors, including GLP-1, GIP, glucagon, and amylin. The mechanism of action typically involves enhancing insulin secretion, suppressing glucagon release, and promoting satiety, which collectively facilitate weight loss and improved metabolic control. However, the stimulation of these receptors, particularly GLP-1 and glucagon, can lead to increased GI motility issues, resulting in nausea, vomiting, and constipation. The incorporation of amylin and Y2 receptor agonism is hypothesized to provide a counterbalance to these effects by modulating gastric emptying and enhancing satiety signals, potentially reducing the incidence of these adverse events.

Key points at a glance

Quad-agonists are designed to target multiple pathways for enhanced metabolic effects.

GI side effects such as nausea and vomiting are common in GLP-1 receptor agonists.

Amylin and Y2 receptor components may mitigate GI side effects.

Current clinical programs include compounds from various sponsors, including Lilly, Novo Nordisk, and Amgen.

Understanding receptor interactions is crucial for optimizing therapeutic profiles.

Future studies will be essential to evaluate the safety and tolerability of these new agents.

Patient adherence is critical for the success of obesity treatments.

Where this fits in the pipeline

Many quad-agonist candidates are currently in various stages of clinical development. For instance, compounds like Mazdutide from Innovent and Survodutide from Boehringer Ingelheim are actively being studied. These programs aim to elucidate the balance between efficacy and tolerability. While specific data on GI side effects is still emerging, early-phase trials will be critical for understanding how these new agents perform compared to existing therapies.

What it could mean for patients

If the GI side effects associated with quad-agonists can be effectively mitigated through the use of amylin and Y2 receptor components, patients may experience improved tolerability and adherence to treatment regimens. This could lead to better outcomes in weight management and metabolic control. However, it is essential to approach these potential benefits with caution, as the safety profiles of these new agents are still being established.

Open questions and what we don't yet know

Despite the promising mechanisms and potential for improved tolerability, several questions remain unanswered. The extent to which amylin and Y2 receptor modulation can effectively reduce GI side effects is still under investigation. Additionally, the long-term safety and efficacy of these quad-agonists in diverse patient populations need to be thoroughly evaluated. Regulatory hurdles may also impact the timeline for these therapies to reach the market, as safety profiles must be well-characterized before approval.

Bottom line

As the pipeline for quad-agonist GLP drugs advances, understanding and addressing GI side effects will be critical for their success. Continued research into receptor interactions and patient outcomes will determine the future landscape of obesity and metabolic treatments.

This article is research-only educational content and is not medical advice. None of the drugs discussed are approved as quad-agonists or penta-agonists at the time of writing.

## Sources